Search

Your search keyword '"Cutillas PR"' showing total 107 results

Search Constraints

Start Over You searched for: Author "Cutillas PR" Remove constraint Author: "Cutillas PR"
107 results on '"Cutillas PR"'

Search Results

1. Guidelines for the use and interpretation of assays for monitoring autophagy (3rd edition). Autophagy

2. Guidelines for the use and interpretation of assays for monitoring autophagy (3rd edition).

4. Guidelines for the use and interpretation of assays for monitoring autophagy (3rd edition)

5. Combined proteomic and metabonomic studies in three genetic forms of the renal Fanconi syndrome

6. Exactly defined molecular weight poly(ethylene glycol) allows for facile identification of PEGylation sites on proteins.

7. Phosphoproteomics predict response to midostaurin plus chemotherapy in independent cohorts of FLT3-mutated acute myeloid leukaemia.

8. A class I PI3K signalling network regulates primary cilia disassembly in normal physiology and disease.

9. Maternal Immune Activation imprints translational dysregulation and differential MAP2 phosphorylation in descendant neural stem cells.

10. Versican Associates with Tumor Immune Phenotype and Limits T-cell Trafficking via Chondroitin Sulfate.

11. Comparison of multiple modalities for drug response prediction with learning curves using neural networks and XGBoost.

12. Causal Role for Neutrophil Elastase in Thoracic Aortic Dissection in Mice.

13. Community detection in empirical kinase networks identifies new potential members of signalling pathways.

14. In Silico Analysis Predicts Nuclear Factors NR2F6 and YAP1 as Mesenchymal Subtype-Specific Therapeutic Targets for Ovarian Cancer Patients.

15. Proteomic Characterization of Acute Myeloid Leukemia for Precision Medicine.

16. Principles of phosphoproteomics and applications in cancer research.

17. HDAC Inhibition Restores Response to HER2-Targeted Therapy in Breast Cancer via PHLDA1 Induction.

18. The CKS1/CKS2 Proteostasis Axis Is Crucial to Maintain Hematopoietic Stem Cell Function.

19. Integrative phosphoproteomics defines two biologically distinct groups of KMT2A rearranged acute myeloid leukaemia with different drug response phenotypes.

20. Microtubule-associated proteins MAP7 and MAP7D1 promote DNA double-strand break repair in the G1 cell cycle phase.

21. Systematic identification of biochemical networks in cancer cells by functional pathway inference analysis.

22. The cytotoxic action of BCI is not dependent on its stated DUSP1 or DUSP6 targets in neuroblastoma cells.

23. CKS1 inhibition depletes leukemic stem cells and protects healthy hematopoietic stem cells in acute myeloid leukemia.

24. eEF2K Activity Determines Synergy to Cotreatment of Cancer Cells With PI3K and MEK Inhibitors.

25. Suppression of Endothelial Cell FAK Expression Reduces Pancreatic Ductal Adenocarcinoma Metastasis after Gemcitabine Treatment.

26. Targeting the lysine-specific demethylase 1 rewires kinase networks and primes leukemia cells for kinase inhibitor treatment.

27. Implementation of Clinical Phosphoproteomics and Proteomics for Personalized Medicine.

28. Computational Analysis of Cholangiocarcinoma Phosphoproteomes Identifies Patient-Specific Drug Targets.

29. TGFBI Production by Macrophages Contributes to an Immunosuppressive Microenvironment in Ovarian Cancer.

30. Targeted therapy for LIMD1-deficient non-small cell lung cancer subtypes.

31. Activating mutations in BRAF disrupt the hypothalamo-pituitary axis leading to hypopituitarism in mice and humans.

32. Drug ranking using machine learning systematically predicts the efficacy of anti-cancer drugs.

33. His452Tyr polymorphism in the human 5-HT 2A receptor affects clozapine-induced signaling networks revealed by quantitative phosphoproteomics.

34. Sequence and Structure-Based Analysis of Specificity Determinants in Eukaryotic Protein Kinases.

35. PARP-1 activation after oxidative insult promotes energy stress-dependent phosphorylation of YAP1 and reduces cell viability.

36. Bespoken Nanoceria: An Effective Treatment in Experimental Hepatocellular Carcinoma.

37. Withanolide Metabolites Inhibit PI3K/AKT and MAPK Pro-Survival Pathways and Induce Apoptosis in Acute Myeloid Leukemia Cells.

38. Characterization of four subtypes in morphologically normal tissue excised proximal and distal to breast cancer.

39. A systematic molecular and pharmacologic evaluation of AKT inhibitors reveals new insight into their biological activity.

40. Cancer Burden Is Controlled by Mural Cell-β3-Integrin Regulated Crosstalk with Tumor Cells.

41. Reconstructing kinase network topologies from phosphoproteomics data reveals cancer-associated rewiring.

42. Cancer associated fibroblast FAK regulates malignant cell metabolism.

43. Poly(ADP-Ribose) Polymerase-1 inhibition potentiates cell death and phosphorylation of DNA damage response proteins in oxidative stressed retinal cells.

44. Perineural invasion in pancreatic cancer: proteomic analysis and in vitro modelling.

45. Oxidative Stress in Cells with Extra Centrosomes Drives Non-Cell-Autonomous Invasion.

46. Endothelial cell rearrangements during vascular patterning require PI3-kinase-mediated inhibition of actomyosin contractility.

47. Shedding of bevacizumab in tumour cells-derived extracellular vesicles as a new therapeutic escape mechanism in glioblastoma.

48. Proteomic and genomic integration identifies kinase and differentiation determinants of kinase inhibitor sensitivity in leukemia cells.

49. Deconstruction of a Metastatic Tumor Microenvironment Reveals a Common Matrix Response in Human Cancers.

50. PHLDA1 Mediates Drug Resistance in Receptor Tyrosine Kinase-Driven Cancer.

Catalog

Books, media, physical & digital resources